Chronic Toxicities Related to Treatment in Patients With Localized Cancer

Launched by UNICANCER · Nov 22, 2013

Keywords

ClinConnect Summary

This clinical trial is studying the long-term side effects of cancer treatments in women with localized (non-metastatic) breast cancer and early-stage lung cancer. The goal is to understand how these treatments affect patients over time, both physically and emotionally, and to identify ways to predict who might experience severe side effects. Researchers aim to gather data from about 14,750 women with breast cancer and later include lung cancer patients. By identifying patients at higher risk for these chronic issues early on, the study hopes to improve their quality of life and reduce healthcare costs by finding better treatment options.

To participate, women must be at least 18 years old, have a confirmed diagnosis of non-metastatic breast or lung cancer, and be fluent in French. They should not have received any treatment for their cancer yet. Participants will share information about their experiences and health, which will help researchers understand the impact of treatment side effects and develop strategies to prevent them. This study is an important step in making cancer treatments safer and more effective for patients.

Gender

FEMALE

Eligibility criteria

• • CANTO - Breast
• Inclusion Criteria:
• • Women,
• • Aged 18 years and over,
• • With an invasive breast cancer diagnosed by cytology or histology,
• • No clinical evidence of metastasis at the time of inclusion,
• • Untreated including scored for breast cancer surgery in progress,
• • Patient receiving a social security system,
• • Patient mastering the French language,
• • Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage.
• * (Since february 2022) Patient :
• • 1. Age \< 45 years at diagnostic
• • 2. Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-
• • 3. Or Eligible to Pembrozilumab, Olaparib, TDM1, Abemaciclib or Ribociclib
• Exclusion Criteria:
• • Metastatic breast cancer,
• • Local recurrence of breast cancer,
• • History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,
• • Already received treatment for breast cancer ongoing,
• • Blood transfusion performed for less than six months,
• • Persons deprived of liberty or under supervision (including guardianship).
• • CANTO - Lung
• Inclusion Criteria:
• • Aged 18 years and over, Having lung cancer diagnosed by cytology or histology or suspected cancer of the lung,
• • Tumor cTX to cT4, cN0-3,
• • No clinical evidence of metastasis at the time of inclusion (patients with metastases on extension assessment within 6 months following diagnosis will be removed from the study),
• • Eligible for curative treatment by surgery or radiotherapy \* (note patients treated with exclusive chemotherapy, exclusive radiotherapy or exclusive stereotactic radiotherapy will be out of study)
• • Lack of treatment received for current lung cancer, including surgical treatment
• • Patient benefiting from a social protection scheme,
• • Patient mastering the French language,
• • Free and informed consent for additional biological samples, the different questionnaires and the collection of information on resource consumption.
• Exclusion Criteria:
• • Metastatic lung cancer,
• • Local relapse of lung cancer,
• • History of cancer within 3 years prior to study entry other than basal cell cutaneous or epithelioma in situ of the cervix,
• • Treatment already received for current lung cancer,
• • Blood transfusion carried out less than 6 months ago,
• • Persons deprived of liberty or under guardianship (including curatorship).